Stockreport

Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory [Seeking Alpha]

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF Sales of Zoryve grew by 675% in Q1 2024 to $21.6 million. The FDA will decide on July 7th, 2024, whether Zoryve should be approved for the treatment of patients with [Read more]